Breaking News - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF)

Breaking News – Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) – RICH TV LIVE – September 22, 2021 – Tryp Therapeutics (CSE:TRYP; OTCQB:TRYPF) (“Tryp”), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it has submitted an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) to evaluate its clinical candidate, TRP-8802, in a Phase 2a study for the treatment of patients with eating disorders. #tryptherapeutics #news #richtvlive

Hey guys how you doing this is rich from rich tv live and richpixdaily.com and i have some breaking news for you today that’s right from trip therapeutics only here on rich tv live and if you guys want to learn the news all you got to do is go and subscribe to rich tv live on youtube and go to richpixdaily.com where you too can join the trading community

Absolutely free or for a vip membership you get access to so much education and rewards and pics like trip therapeutics where we believe have enormous upside potential now let’s talk about the news that is breaking right now trip therapeutic submits ind application for phase 2 a clinical trial in eating disorders that’s right trip therapeutics tryp in canada as

You see in the sign trypf in america on the otcqb exchange a pharmaceutical company focused on developing psilocybin-based compounds for disease with unmet medical needs announced today that it has submitted an investigational new drug ind application to the u.s food and drug administration fda to evaluate its clinical candidate trip trp-8802 in a phase to

A study for the treatment of patients with eating disorders the trial is being conducted with jennifer miller md from the university of florida and will evaluate the company’s oral formulation of synthetic psilocybin trip dash 8802 in combination with psychotherapy told you guys i love psychedelics this is just the beginning for psychedelics they do not even

Have fda approval and i believe that the upside is tremendous the ind application represents a critical step in the drug development process for determining the effectiveness of trip 8802 for overeating disorders trip expects to initiate phase 2 a study in q4 of this year which is pretty much right now subject to a favorable review of the ind by the fda we

Are walking in to q4 as we speak the submission of this ind represents hundreds of hours of collaborative preparation design and coordination between trip and the team at the university of florida as we pursue a leading edge treatment of psilocybin with psychotherapy commented dr miller i have thoroughly enjoyed working with the team at trip and our shared

Commitment to exploring new treatments for our patients who have so few existing therapies available to them because this is still the early days for psychedelics the phase ii clinical trial is expected to enroll 10 patients and various overeating disorders including binge eating disorder hypothalamic obesity and prater willy syndrome the administration of

Psilocybin is reported in the literature to increase neuroplasticity leading to newly formed neural networks which may which may improve eating behavior patients will meet with psychotherapists who have been trained by fluence for two sessions prior to the administration of trip 8802 which will take place in two drug dosing sessions integration sessions with

The psychotherapist will be conducted after the administration of the drug this ind submission marks the most important milestone the company has achieved to date and will be critical in identifying patients responses to trip 8802 the result from this study will also provide critical information to support our proprietary drug candidate trip 8803 that will

Be used in phase 2b trials and beyond commented greg mckee chairman and executive officer of trip this is the first of several ind filings we expect to make in the coming months in support of our work to address various chronic pain and eating disorder indications and we are eager to begin enrolling our first patients in multiple phase 2a trials later this

Year about trip therapeutics and i think guys i’m going to show you guys the chart that we’re right at the bottom here trip therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways tripped psilocybin for neuro psychiatric disorders

Pfn programs is focused on the development and synthetic psilocybin as a new class of drug for the treatment of chronic pain and other indications the company has announced upcoming face to a clinical trials with the university of michigan and the university of florida to evaluate its drug products for fibromyalgia and overeating disorders respectively trip

Is also developing a proprietary psilocybin based product trip 8803 that uses a novel formulation and route of administration to improve the patient experience big news breaking news for trip therapeutics who has now submitted ind application for face to a clinical trial in eating disorders now i want to show you guys what i see here with this company early

Stage psychedelics company this is a company that is a medicinal company it is i believe going to be groundbreaking technology for potentially for eating disorders and other pain and you can see here the market cap i love the market cap only a 24 million market cap that’s a baby market cap and only 66 million shares so a very tight share structure so i’m very

Impressed with the share structure the website right here i’m going to show you guys is trip therapeutics.com you can see you can subscribe right here i’m going to subscribe further updates just hit subscribe and then you get put on their mailing list just like that which i’ve done oh look it says right here you’ve already subscribed to trip therapeutic so

I’m already in there so no need for me to subscribe again i am already a subscriber okay this is their website i’m not going to go through the website right now but you can see pretty cool website has everything you need on it right here you can see their twitter page their linkedin page their us symbol their canadian sybil home leadership pipeline investor

Information news and contact all of that is there trip therapeutics is leading the next wave of psychedelic drug development beyond mental health and i’m telling you guys this is a new era for psylocybin and companies like trip are leading the charge so tight share structure big breaking news working on fda approval and let’s take a look at the stock in the

Share price so you can see that they’ve been as high as a dollar 20 and that to me is kind of a sign of what’s to come okay so they’re kind of showing their hand if the company’s successful maybe we see them go back to a dollar twenty well the low low is 35 cents and we’re currently sitting at 36. so we’re the lowest pretty much it’s ever been okay despite

The fact that it is a growing company and it’s got big breaking news so as a trader you need to be aware that it’s closer to the bottom than it is to the top i don’t think the downside pressure or there is i don’t believe that there should be as much downward pressure from these prices onward but you never know always remember that rich tv live is strictly

For information education purposes past performance is not an indication of future results so just like this has come down doesn’t mean that it will continue to go down but it also doesn’t mean that it can’t go up so we’ve seen it go as high as a dollar 20 before it’s currently at 35 where do you think it goes in the future love to know what you guys think